Target
ribociclib
2 abstracts
Abstract
Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.Org: Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, University of British Columbia, Vancouver, BC, Canada, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada, University of Victoria, Victoria, BC, Canada, Canadian Cancer Society, Toronto, ON, Canada, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Patient Partner, Toronto, ON, Canada, University of Alberta, Edmonton, AB, Canada, BC Cancer/ University of British Columbia, Vancouver, BC, Canada, BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada, Princess Margaret Cancer Centre, University of Toronto,
Abstract
Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA.Org: Onkologie Ravensburg, University Women’s Hospital, Paracelsus Medical University, Winicker Norimed GmbH, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,